Featured Research

from universities, journals, and other organizations

Newly Refined Antibody Therapy May Be Potent Treatment For Autoimmune Diseases

Date:
April 30, 2008
Source:
Rockefeller University
Summary:
An old, fickle therapy for a variety of autoimmune diseases is getting a makeover, thanks to a decade-long investigation. The original treatment, called intravenous immunoglobulin or IVIG, is an amalgam of specific antibodies made from the pooled blood plasma of thousands of healthy donors. Physicians have used it both on-label and off in patients with lupus, arthritis, asthma and other immune disorders, to varying degrees of success. But new research shows that understanding how the therapy works at a molecular level can help researchers create a version in the lab that's many times more potent.

An old, fickle therapy for a variety of autoimmune diseases is getting a makeover, thanks to a decade-long investigation by Rockefeller University researchers. The original treatment, called intravenous immunoglobulin or IVIG, is an amalgam of specific antibodies made from the pooled blood plasma of thousands of healthy donors.
Credit: Image courtesy of Rockefeller University

An old, fickle therapy for a variety of autoimmune diseases is getting a makeover, thanks to a decade-long investigation by Rockefeller University researchers. The original treatment, called intravenous immunoglobulin or IVIG, is an amalgam of specific antibodies made from the pooled blood plasma of thousands of healthy donors. Physicians have used it both on-label and off in patients with lupus, arthritis, asthma and other immune disorders, to varying degrees of success. But new research shows that understanding how the therapy works at a molecular level can help researchers create a version in the lab that’s many times more potent.

Jeffrey Ravetch, Theresa and Eugene M. Lang Professor and head of the Leonard Wagner Laboratory of Molecular Genetics and Immunology, has been interested in IVIG ever since he became aware of its inherent paradox: IgG antibodies, the very class of antibodies that triggers autoimmune diseases, give IVIG its anti-inflammatory properties when pooled from healthy donors. In 2006, Ravetch and his colleagues discovered that this apparent contradiction could be attributed to a single sugar molecule called sialic acid, located at the very tip of some IgG antibodies. When present, the molecule confers anti-inflammatory properties. When absent, the IgG molecules lose their protective abilities and can actually cause inflammation.

Once the scientists had pinned down the molecular mechanism at the source of the contradiction and proved that they could map out a strategy for building a drug with the therapeutic properties of IVIG, they set about creating it. Ravetch, together with his collaborators at the University of New Hampshire and The Scripps Research Institute, produced an engineered, sialylated IgG molecule that — when given to arthritic mice — was about 30 times more effective than IVIG alone. “This paper provides a clear route for developing an alternative for IVIG, which could be of great benefit to patients with autoimmune diseases,” Ravetch says. The results, reported in the latest issue of Science, also describe the precise structural requirements needed to create IgG with protective properties.

Rockefeller has licensed the technology to the biotechnology company Centaurus Pharmaceuticals, which is working to create a product that can be used in clinical trials. Ravetch believes that the resulting drug will have the potential to provide relief to people with a wide range of ailments, including those for whom IVIG just barely scratches the surface. In lupus, for instance, the current preparation has such low activity that the amount required to effect a noticeable difference exceeds the amount that can be realistically derived from the blood supply. “But with the recombinant form,” Ravetch says, “you can make an unlimited, potent supply.”

Journal reference: Recapitulation of IVIG Anti-Inflammatory Activity with a Recombinant IgG Fc. Science 320 (5874): 373–376 (April 18, 2008)


Story Source:

The above story is based on materials provided by Rockefeller University. Note: Materials may be edited for content and length.


Cite This Page:

Rockefeller University. "Newly Refined Antibody Therapy May Be Potent Treatment For Autoimmune Diseases." ScienceDaily. ScienceDaily, 30 April 2008. <www.sciencedaily.com/releases/2008/04/080428145012.htm>.
Rockefeller University. (2008, April 30). Newly Refined Antibody Therapy May Be Potent Treatment For Autoimmune Diseases. ScienceDaily. Retrieved August 1, 2014 from www.sciencedaily.com/releases/2008/04/080428145012.htm
Rockefeller University. "Newly Refined Antibody Therapy May Be Potent Treatment For Autoimmune Diseases." ScienceDaily. www.sciencedaily.com/releases/2008/04/080428145012.htm (accessed August 1, 2014).

Share This




More Health & Medicine News

Friday, August 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

House Republicans Vote to Sue Obama Over Healthcare Law

House Republicans Vote to Sue Obama Over Healthcare Law

Reuters - US Online Video (July 31, 2014) The Republican-led House of Representatives votes to sue President Obama, accusing him of overstepping his executive authority in making changes to the Affordable Care Act. Mana Rabiee reports. Video provided by Reuters
Powered by NewsLook.com
Despite Health Questions, E-Cigs Are Beneficial: Study

Despite Health Questions, E-Cigs Are Beneficial: Study

Newsy (July 31, 2014) Citing 81 previous studies, new research out of London suggests the benefits of smoking e-cigarettes instead of regular ones outweighs the risks. Video provided by Newsy
Powered by NewsLook.com
Dangerous Bacteria Kills One in Florida

Dangerous Bacteria Kills One in Florida

AP (July 31, 2014) Sarasota County, Florida health officials have issued a warning against eating raw oysters and exposing open wounds to coastal and inland waters after a dangerous bacteria killed one person and made another sick. (July 31) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins